Studying Pathways of Resistance in KRAS-driven Cancers

Active, not recruitingOBSERVATIONAL

Enrollment

500

Participants

Timeline

Start Date

September 8, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

March 31, 2026

Conditions

KRAS P.G12C

Interventions

DIAGNOSTIC_TEST

FoundationOne® Liquid CDx

The FoundationOne® Liquid CDx is an FDA-approved companion diagnostic that analyzes guideline-recommended genes from a simple blood draw.

Trial Locations (1)

Dana-Farber Cancer Institute, Boston

All Listed Sponsors

lead

Addario Lung Cancer Medical Institute

OTHER